8-K: Novanta Exceeds Q3 Expectations, Projects Strong 2026 Growth

Novanta Inc. reported third-quarter 2025 financial results exceeding revenue, profit, and Adjusted EPS expectations, driven by Advanced Surgery growth and new product revenues.

Summary

• GAAP Revenue for Q3 2025 increased 1.4% to $247.8 million, compared to $244.4 million in Q3 2024.
• GAAP Net Income for Q3 2025 was $10.7 million, a decrease from $19.2 million in Q3 2024.
• GAAP Diluted Earnings Per Share (EPS) was $0.30 in Q3 2025, down from $0.53 in Q3 2024.
• Adjusted EBITDA for Q3 2025 increased to $58.1 million, from $57.0 million in Q3 2024.
• Adjusted EPS for Q3 2025 was $0.87, up from $0.85 in Q3 2024.
• Organic Revenue Growth was (3.8)% for Q3 2025.
• The company achieved a book-to-bill ratio of 1.03x and saw 17% bookings growth year-over-year.
• Operating cash flow for Q3 2025 was $8.5 million, a decrease from $23.0 million in Q3 2024, primarily due to increased inventory purchases for manufacturing relocation and timing of tax/acquisition/restructuring activities.
• Acquisition activities contributed a net increase of $8.4 million (3.4%) to revenue, and foreign currency exchange rates favorably impacted revenue by $4.4 million (1.8%).

Sentiment

Score: 7

Explanation: While GAAP net income and EPS declined, and organic revenue growth was negative, the company exceeded its internal expectations for adjusted metrics. Strong forward guidance, positive book-to-bill, and bookings growth indicate a positive outlook and management's confidence in future recovery and growth, balancing the current GAAP declines.

Positives

• Exceeded expectations for revenue, profit, and Adjusted EPS growth in Q3 2025.
• Reported improving business fundamentals and strength from continued new product revenues.
• Experienced significant growth in the Advanced Surgery business segment.
• Achieved a book-to-bill ratio of 1.03x, indicating more orders received than shipped.
• Saw 17% bookings growth year-over-year.
• Anticipates a return to year-over-year organic growth in Q4 2025, with mid to high single-digit reported growth.
• Expects solid double-digit Adjusted EPS growth in Q4 2025.
• Full year 2025 new product revenue is expected to exceed $50 million, driven by strength in the Medical Solutions segment.
• Projects mid-single digit organic revenue growth for full year 2026 due to continued business momentum, new design wins, and product launches.

Negatives

• GAAP Net Income decreased to $10.7 million in Q3 2025 from $19.2 million in Q3 2024.
• GAAP Diluted EPS decreased to $0.30 in Q3 2025 from $0.53 in Q3 2024.
• Organic Revenue Growth was negative (3.8)% for Q3 2025.
• GAAP Operating Income decreased to $21.8 million in Q3 2025 from $32.6 million in Q3 2024.
• Operating cash flow decreased significantly to $8.5 million in Q3 2025 from $23.0 million in Q3 2024, primarily due to increased inventory purchases for manufacturing relocation and timing of tax payments, acquisition, and restructuring activities.
• Restructuring, acquisition, and related costs increased to $6.7 million in Q3 2025 from $2.5 million in Q3 2024.
• Selling, general and administrative expenses increased to $51.4 million in Q3 2025 from $44.3 million in Q3 2024.

Risks

• Economic and political conditions and their effects on customer businesses, capital expenditures, and business activities.
• Dependence on the ability to respond to fluctuations in product demand.
• Ability to continuously innovate, introduce new products in a timely manner, and manage transitions to new product innovations effectively.
• Customer order timing and other similar factors.
• Disruptions or breaches in security of IT systems, including those of third-party providers.
• Risks associated with operations in foreign countries and increased use of outsourcing.
• Exposure to increased tariffs, trade restrictions, or taxes on products.
• Ability to contain or reduce costs.
• Violations of intellectual property rights and the ability to protect intellectual property against infringement.
• Risk of losing competitive advantage.
• Failure to successfully integrate recent and future acquisitions into the business.
• Ability to attract and retain key personnel.
• Restructuring and realignment activities.
• Product defects or problems integrating products with other vendors' products.
• Disruptions in the supply of certain key components and other goods from suppliers.
• Failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments.
• Production difficulties and product delivery delays or disruptions.
• Exposure to extensive medical device regulations, which may impede or hinder product approval, certification, or sale.
• Potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations.
• Impact of healthcare industry cost containment and healthcare reform measures.
• Changes in governmental regulations related to the business or products.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws.
• Failure to implement new information technology systems successfully.
• Changes in foreign currency rates.
• Failure to realize the full value of intangible assets.
• Reliance on original equipment manufacturer customers.
• Loss of sales, or significant reduction in orders from, any major customers.
• Increasing scrutiny and changing expectations from investors, customers, governments, and other stakeholders with respect to corporate sustainability policies.
• The effects of climate change and related regulatory responses.
• Exposure to the credit risk of some customers and in weakened markets.
• Being subject to U.S. federal income taxation even as a non-U.S. corporation.
• Changes in tax laws and fluctuations in effective tax rates.
• Any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance existing indebtedness, which may not be available on acceptable terms or at all.
• Existing indebtedness limiting the ability to engage in certain activities.
• Volatility in the market price for common shares.
• Failure to maintain appropriate internal controls in the future.

Future Outlook

For Q4 2025, Novanta expects GAAP revenue of approximately $253 million to $257 million, Adjusted EBITDA in the range of $62 million to $65 million, and Adjusted Diluted EPS between $0.87 and $0.93. The company anticipates a return to year-over-year organic growth (mid to high single-digit reported growth) and solid double-digit Adjusted EPS growth. For the full year 2025, GAAP revenue is projected to be $975 million to $979 million, Adjusted EBITDA $222 million to $225 million, and Adjusted Diluted EPS $3.24 to $3.30, with new product revenue expected to exceed $50 million. Looking to full year 2026, Novanta expects mid-single digit organic revenue growth driven by continued business momentum, new design wins, and product launches.

Management Comments

• "We exceeded our expectations for revenue, profit and Adjusted EPS growth in the third quarter, based on improving business fundamentals, strength of continued new product revenues and significant growth in our Advanced Surgery business." Matthijs Glastra, Chair and Chief Executive Officer.
• "In addition, we achieved a book-to-bill of 1.03x and saw 17% bookings growth year-over-year." Matthijs Glastra.
• "We are proud of our teams' execution in achieving these results as we have been successfully navigating a complex macroenvironment." Matthijs Glastra.
• "As underlying fundamentals begin to recover across various end markets we serve, in the fourth quarter we expect to see a return to year-over-year organic growth (mid to high single digit reported growth), and solid double-digit Adjusted EPS growth." Matthijs Glastra.
• "For the full year, we are confident in our ability to deliver on our financial objectives as incremental new product revenue remains on track and is expected to exceed $50 million given particular strength in our Medical Solutions segment." Matthijs Glastra.
• "Looking forward to full year 2026, we now expect to deliver mid-single digit organic revenue growth as a result of continued momentum in our business and end markets, the strength of new design wins, and our new product launches." Matthijs Glastra.

Industry Context

Novanta operates as a leading global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers (OEMs). The company leverages proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. The reported results indicate that while the company is navigating a complex macroenvironment, underlying fundamentals are beginning to recover across its diverse end markets, with particular strength noted in the Medical Solutions segment. This suggests a resilient position within its specialized high-tech sectors, despite broader economic headwinds.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Novanta's performance against global benchmarks.

Stakeholder Impact

• Shareholders: Mixed Q3 GAAP results but positive adjusted performance and strong future guidance could lead to increased investor confidence and potential share price appreciation.
• Employees: Management praised teams' execution in navigating a complex macroenvironment. Restructuring activities are ongoing, which may have implications for employees, though no specific details are provided.
• Customers: Continued new product revenues and design wins suggest strong customer relationships and successful product adoption.
• Suppliers: Increased inventory purchases related to manufacturing relocation may impact supplier demand and relationships.
• Creditors: Existing indebtedness is noted as a risk factor, but no immediate impact or changes are detailed in the filing.

Next Steps

• Host a conference call on November 4, 2025, at 8:30 a.m. ET to discuss these results and provide a business update.
• Continue to execute the plan to relocate certain manufacturing production, which is currently driving increased inventory purchases.
• Focus on new product launches and design wins to drive continued momentum and achieve mid-single digit organic revenue growth in 2026.

Key Dates

Recommendation

Novanta Inc. reported a mixed third quarter, with GAAP net income and diluted EPS declining year-over-year, and organic revenue growth remaining negative at (3.8)%. However, the company exceeded its internal expectations for revenue, profit, and Adjusted EPS, driven by strong performance in its Advanced Surgery business and new product revenues. Adjusted EBITDA and Adjusted EPS showed modest growth. Management's forward guidance is optimistic, projecting a return to year-over-year organic growth in Q4 2025 and mid-single-digit organic revenue growth for full year 2026, alongside solid double-digit Adjusted EPS growth. The positive book-to-bill ratio and bookings growth are encouraging. While the adjusted results and future outlook are positive, the decline in GAAP profitability and negative organic growth warrant a cautious approach. Investors should hold to monitor the execution of the strategic initiatives and the anticipated recovery in organic growth.

Keywords

Novanta, NOVT, financial results, Q3 2025, earnings, revenue, net income, EPS, EBITDA, medical technology, advanced technology, manufacturing, robotics, automation, precision medicine, advanced surgery, OEM, financial guidance